Abstract: The invention relates to E-5-(2-halogenovinyl)-2'-deoxycytidines, e.g. E-5-(bromovinyl)-2'-deoxycytidine and E-5-(2-iodovinyl)-2'-deoxycytidine. These substances are endowed with specific antiviral activities towards herpes simplex virus and with an extremely low toxicity which makes them useful in antiviral medicines and for treatment of virus diseases in man and animal. They may be synthesized by introduction of an E-5-(2-halogenovinyl) sidechain into 2'-deoxycytidine, or by condensation of a trialkylsilyl derivative of E-5-(2-halogenovinyl)-cytosine with a hydroxyl-protected reactive derivative of 2'-deoxy-D-erythro-pentofuranose.

Abstract: Human fibroblast interferon may be purified to a high degree by using a simple two-step purification method comprising (a) subjecting an aqueous interferon solution to chromatography on porous glass beads, and (b) subjecting the resulting aqueous interferon solution to chromatography on immobilized zinc chelate. Overall recoveries of about 45-76% of the initial interferon activity may be achieved and the end product will be free of any skin reactive agents.

Abstract: The specification describes the use of S or RS 9-(2, 3-dihydroxypropyl) adenine either alone or in combination with ara-A for the treatment of virus diseases.

Abstract: An aqueous interferon solution which comprises contaminating proteins can be purified by chromatography on porous glass beads. The elution is effected at an acid pH.

Abstract: An aqueous interferon solution is stabilized by treatment with a combination of (a) an agent for disrupting non-covalent bonds, (b) an agent for reducing disulfide bridges, and (c) an anionic or cationic surface-active agent.